Akari Therapeutics was established in 2005 in the UK. The company is currently public and trades on NASDAQ under AKTX.
75/76 Wimpole Street London W1G 9RT UK
T: +44 (0)20.8004.0261
New York, NY 10036
For investor relations inquiries: IR@akaritx.com
For business development inquiries: BD@akaritx.com
In severe or life-threatening conditions where there are no available treatment options, regulators may grant permission to provide a treating physician access to an unapproved drug; this is known as expanded access. At this time, the safety and effectiveness of nomacopan to treat diseases such as Atopic Keratoconjunctivitis (AKC), Bullous Pemphigoid (BP); Thrombotic Microangiopathy (TMA), and Paroxysmal Nocturnal Hemoglobinuria (PNH) has not been established. Until more data are available, Akari Therapeutics is not considering requests for expanded access outside of clinical trials. This policy may change as safety and efficacy are better demonstrated. For questions regarding our current expanded access policy, please contact Akari Therapeutics at +44 (0)20-8004-0261.